- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05011422
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
A Pilot Study of Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jeffrey Bednarski, M.D., Ph.D.
- Phone Number: 314-286-2825
- Email: bednarski_j@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Jeffrey Bednarski, M.D., Ph.D.
- Phone Number: 314-286-2825
- Email: bednarski_j@wustl.edu
-
Sub-Investigator:
- Megha Malhotra, M.D.
-
Sub-Investigator:
- Rachel Langley, PharmD
-
Sub-Investigator:
- Thomas Pfeiffer, M.D.
-
Sub-Investigator:
- Melissa Mavers, M.D., Ph.D.
-
Sub-Investigator:
- Feng Gao, Ph.D.
-
Sub-Investigator:
- Shalini Shenoy, M.D.
-
Sub-Investigator:
- Robert Hayashi, M.D.
-
Principal Investigator:
- Jeffrey Bednarski, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Recipient Inclusion Criteria:
Must meet at least one of the following disease criteria:
B cell ALL in first remission and any of the following:
Persistent flow-based MRD at end-of-consolidation:
- >= 1% for NCI SR ALL
- >= 0.01% for NCI HR ALL
- TCF3-HLF t(17;19)
- KMT2A rearranged infant ALL, < 6 months of age and presenting WBC of > 300,000 or poor steroid response (peripheral blasts >= 1000 /uL on day 8 of therapy
- Other high-risk features not explicitly stated here, after discussion/approval with protocol PI.
B cell ALL in second remission and any of the following:
- Early (<36 months from start of therapy) marrow or combined relapse
- Late (>36 months from start of therapy) marrow or combined relapse with end-of re-induction flow MRD >= 0.1%
- Early isolated extramedullary relapse (< 18 months from start of therapy)
- Any B cell ALL in third or greater remission
T cell ALL in first remission
- End-of consolidation MRD > 0.1%
- Any T cell ALL in second or greater remission
AML in first remission with any of the following high-risk features:
- MRD >= 1% after first induction course
- MRD >= 0.1% after second induction course
- RPN1-MECOM
- RUNX1-MECOM
- NPM1-MLF1
- DEK-NUP214
- KAT6A-CREBBP (if >= 90 days at diagnosis)
- FUS-ERG
- KMT2A-AFF1
- KMT2A-AFDN
- KMT2A-ABI1
- KMT2A-MLLT1
- 11p15 rearrangement (NUP98 - any partner gene)
- 12p13.2 rearrangement (ETV6 - any partner gene)
- Deletion 12p to include 12p13.2 (loss of ETV6)
- Monosomy 5/Del(5q) to include 5q31 (loss of EGR1)
- Monosomy 7
- 10p12.3 rearrangement (MLLT10b - any partner gene)
- FLT3/ITD with allelic ratio > 0.1%
- RAM phenotype as evidenced by flow cytometry: bright CD56+, dim to negative CD45 and CD38 and lack of HLA-DR
- Other high-risk features not explicitly stated here, after discussion/approval with protocol PI.
- AML in second or greater remission
- Mixed phenotype or undifferentiated leukemia in any CR
- Secondary to therapy-associated leukemia in any CR
- NK cell lineage leukemia in any CR
- Myelodysplastic syndrome (MDS)
- Juvenile myelomonocytic leukemia (JMML)
- May have undergone a prior hematopoietic stem cell transplant provided one of the criteria in Inclusion Criterion #1 are met AND the patient does not have active GVHD (has been off immunosuppression for at least 3 months).
- Available familial haploidentical donor.
- Donor and recipient must be identical at a minimum of one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A minimum of 5/10 match is required and will be considered sufficient evidence that the donor and recipient share one HLA haplotype.
- No more than 30 years of age
- Lansky or Karnofsky performance status > 50%
Adequate organ function as defined below:
- Cardiac: LVEF ≥ 40% at rest or SF ≥ 26%
Hepatic:
- Total bilirubin < 3 x IULN for age
- AST(SGOT)/ALT(SGPT) < 5 x IULN
- Renal: GFR ≥ 60 mL/min/1.73m2 as estimated by updated Schwartz formula for ages 1-17 years (see Appendix B), 24-hour creatinine clearance, or renal scintigraphy. If GFR is abnormal for age based on updated Schwartz formula, accurate measurement should be obtained by either 24-hour creatinine clearance or renal scintigraphy. Renal function may also be estimated by serum creatinine based on age/gender. A minimum serum creatinine of 2x upper limit of normal is required for inclusion on this protocol.
Pulmonary:
- O2 saturation ≥ 92% on room air without positive pressure support
- FEV1, FVC, and DLCO ≥ 50% of predicted (for children unable to perform a pulmonary function test, a high-resolution CT chest may be obtained)
- The effects of these treatments on the developing human fetus are unknown. For this reason, patients of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for 24 months following transplant. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Recipient Exclusion Criteria:
- Available matched related donor. A patient with a matched unrelated donor is eligible if urgent transplantation is required. A prior unrelated donor search is not required for enrollment.
- Active non-hematologic malignancy. History of other malignancy is acceptable as long as therapy has been complete and there is no evidence of disease.
- Currently receiving any other investigational agents.
- Active CNS or extramedullary disease. History of CNS or extramedullary disease now in remission is acceptable.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to conditioning agents used in the study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (bacterial, viral with clinical instability, or fungal), symptomatic congestive heart failure, or unstable cardiac arrhythmia.
- Presence of significant anti-donor HLA antibodies per institutional standards. Anti-donor HLA Antibody Testing is defined as a positive crossmatch test of any titer (by complement dependent cytotoxicity or flow cytometric testing) or the mean fluorescence intensity (MFI) of any anti-donor HLA antibody by solid phase immunoassay.
- Presence of a second major disorder deemed a contraindication for HSCT.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of the start of conditioning.
Donor Eligibility Criteria:
- At least 6 months of age
- Meets the selection criteria as defined by the Foundation for the Accreditation of Hematopoietic Cell Therapy (FACT).
- Able to understand and willing to sign an IRB-approved written informed consent document (or that of legally authorized representative, if applicable).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ex vivo αβ-TCR/CD19 depleted haplo-hematopoietic stem cell infusion (HSCT)
|
Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations.
It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads.
After labeling, the cells are washed to remove unbound microbeads.
The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device.
The negative fraction is centrifuged and volume reconstituted to obtain the final product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by the number of events occurring within the first 100 days post-transplant
Time Frame: Through 100 days post-transplant
|
-Events are death, disease recurrence or progression, and graft failure
|
Through 100 days post-transplant
|
Engraftment as measured by time to neutrophil count recovery
Time Frame: From day of transplant (day 0) to 42 days (+/- 14 days) post transplant
|
Time to neutrophil recovery is defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of >500/μL after conditioning.
|
From day of transplant (day 0) to 42 days (+/- 14 days) post transplant
|
Engraftment as measured by time to platelet count recovery
Time Frame: From day of transplant (day 0) to 75 days (+/- 14 days) post transplant)
|
Time to platelet recovery is defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count > 50,000/μL AND did not receive a platelet transfusion in the previous 7 days.
The exception is the case in which a patient receives platelet transfusions specifically to achieve a higher platelet threshold to allow for an invasive procedure or protection if determined to be at elevated bleeding risk.
|
From day of transplant (day 0) to 75 days (+/- 14 days) post transplant)
|
Donor cell chimerism as measured by short tandem repeat analysis
Time Frame: Through day +100
|
|
Through day +100
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event free survival (EFS)
Time Frame: At 2 years post transplant
|
-Death, disease recurrence or progression, and graft failure are considered events
|
At 2 years post transplant
|
Change in Lansky/Karnofsky performance score
Time Frame: Day +14, Day +30, Day +60, Day +100, Day +180, Day +365, +18 months, and +24 months
|
|
Day +14, Day +30, Day +60, Day +100, Day +180, Day +365, +18 months, and +24 months
|
Incidence and severity of acute GVHD
Time Frame: Weekly through day +100
|
-Incidence and severity of acute GVHD as graded according to the NIH consensus criteria.
Severe aGVHD (Grades III-IV) is considered an event.
|
Weekly through day +100
|
Incidence and severity of chronic GVHD
Time Frame: Day 101 through 24 months
|
Incidence and severity of acute GVHD as graded according to the NIH consensus criteria.
Severe cGHVD is considered an event.
|
Day 101 through 24 months
|
Number of neurologic toxicities
Time Frame: Through 24 months
|
-As evidence by clinical assessment and/or imaging at physician discretion
|
Through 24 months
|
Number of pulmonary toxicities
Time Frame: Through 24 months
|
-As determined by clinical context and serial assessment of TLC, FVC, FEV1, DLCO, or high-resolution CT Chest
|
Through 24 months
|
Number of cardiac toxicities
Time Frame: Through 24 months
|
-As determined by clinical assessment and EKG and/or echocardiogram
|
Through 24 months
|
Number of renal toxicities
Time Frame: Through 24 months
|
-As determined by clinical assessment and BUN, creatinine, urinalysis, estimated GFR, or renal scintigraphy
|
Through 24 months
|
Number of hepatic toxicities
Time Frame: Through 24 months
|
-As determined by clinical assessment and liver function tests
|
Through 24 months
|
Number of participants with infections
Time Frame: Through 24 months
|
Through 24 months
|
|
Number of metabolic toxicities
Time Frame: Through 24 months
|
-Metabolic toxicities will be collected using a complete metabolic panel
|
Through 24 months
|
Number of thyroid toxicities
Time Frame: Through 24 months
|
-Thyroid toxicities will be collected using a thyroid function test
|
Through 24 months
|
Immune reconstitution as measured by recovery of absolute neutrophil count
Time Frame: Over 24 months
|
Over 24 months
|
|
Immune reconstitution as measured by recovery of absolute monocyte count
Time Frame: Over 24 months
|
Over 24 months
|
|
Immune reconstitution as measured by regain of function of NK cell populations
Time Frame: Over 24 months
|
|
Over 24 months
|
Immune reconstitution as measured by regain of function of T cell populations
Time Frame: Through 24 months
|
|
Through 24 months
|
Immune reconstitution as measured by regain of function of B cell populations
Time Frame: Through 24 months
|
|
Through 24 months
|
Immune reconstitution as measured by regain of function of immunoglobulin G (IgG)
Time Frame: Over 24 months
|
|
Over 24 months
|
Immune reconstitution as measured by regain of function of immunoglobulin A (IgA)
Time Frame: Over 24 months
|
|
Over 24 months
|
Immune reconstitution as measured by regain of function of immunoglobulin M (IgM)
Time Frame: Over 24 months
|
|
Over 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jeffrey Bednarski, M.D., Ph.D., Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202203051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Hematologic Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
AstraZenecaActive, not recruitingPediatric Cancer | Hematological Malignancies | Solid Tumor PediatricSpain, Italy, United States, United Kingdom, France, Netherlands, Germany
-
National Cancer Institute (NCI)Enrolling by invitationSolid Tumors | Hematologic Malignancies | Pediatric CancersUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Cooperative Study Group A for HematologyCompletedHEMATOLOGIC MALIGNANCIESKorea, Republic of
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Medical College of WisconsinCompletedMalignancies, HematologicUnited States
-
Sinocelltech Ltd.RecruitingRelapsed or Refractory Hematologic MalignanciesChina
-
Vanda PharmaceuticalsUnknownRelapsed or Refractory Hematologic MalignanciesUnited States
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
Clinical Trials on Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
-
Children's Hospital of PhiladelphiaAvailableLeukemia | Immunodeficiencies | Bone Marrow Failure SyndromeUnited States
-
Julie-An M. TalanoMiltenyi Biotec, Inc.Active, not recruitingHematologic MalignanciesUnited States
-
Children's Hospital of PhiladelphiaUniversity of California, San FranciscoRecruitingImmunodeficiencies | Immune Dysregulation SyndromesUnited States
-
University of Kansas Medical CenterIn8bio Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid LeukemiaUnited States
-
Children's Hospital of PhiladelphiaRecruitingLymphoma | Leukemia | MyelodysplasiaUnited States
-
Sumithira VasuRecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditionsUnited States
-
Washington University School of MedicineThe Leukemia and Lymphoma Society; Rising Tide Foundation; St. Louis Children...Not yet recruitingAcute Myeloid Leukemia | Aml | AML, Childhood | Acute Myeloid Leukemia, PediatricUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1United States, Puerto Rico, Israel
-
National Cancer Institute (NCI)Not yet recruiting